-
Definium Therapeutics Inc (DFTX) PT Raised to $67 at Stifel
-
Definium Therapeutics (DFTX) Halted, News Pending
-
Stifel Reiterates Buy Rating on Definium Therapeutics Inc (DFTX)
-
Definium Therapeutics (DFTX) call put ratio 1 call to 1.9 puts as share price down 3.6%
-
Stifel Reiterates Buy Rating on Definium Therapeutics Inc (DFTX)
-
Stifel on Definium Therapeutics (DFTX) Post Mgmt Dinner Meet: 'Confident Overall in Regulatory/Commercial Dynamics'
-
BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy
-
Definium Therapeutics Inc (DFTX) PT Raised to $64 at Canaccord
-
Mind Medicine (DFTX) Misses Q2 EPS by 144c
-
Wells Fargo sees psychedelics market reaching $11B by 2035
-
Definium Therapeutics Inc (DFTX) PT Raised to $73 at Piper Sandler Ahead For DT120
-
Definium Therapeutics launches GAD education program for providers
-
Definium Therapeutics Inc (DFTX) PT Raised to $60 at Stifel
-
Definium Therapeutics Inc (DFTX) PT Lowered to $58 at Canaccord
-
Definium Therapeutics Inc (DFTX) PT Raised to $50 at Needham
-
Definium Therapeutics Inc (DFTX) PT Raised to $60 at Oppenheimer
-
Definium Therapeutics Inc (DFTX) PT Raised to $52 at Leerink
-
RBC Capital Reiterates Outperform Rating on Definium Therapeutics Inc (DFTX), sees favorable set up
-
Definium Therapeutics, Inc. (DFTX) Misses Q1 EPS by 23c
-
Definium Therapeutics (DFTX) Reiterated at Buy by Stifel After Analyst Day
-
H.C. Wainwright Reiterates Buy Rating on Definium Therapeutics Inc (DFTX)
-
Piper Sandler Reiterates Overweight Rating on Definium Therapeutics Inc (DFTX)
-
Definium Therapeutics updates DT120 clinical trials and commercial plans
-
Psychedelic stocks soar after Trump signs executive order to fast-track treatments
-
Stifel Starts Definium Therapeutics Inc (DFTX) at Buy
-
White House Prepares Order On Ibogaine Psychedelic - CBS
-
Piper Sandler Starts Definium Therapeutics Inc (DFTX) at Overweight
-
Definium study shows anxiety disorder prevalence rose to 6.6% in 2023
-
Wolfe Research Starts Definium Therapeutics Inc (DFTX) at Outperform, Top Pick
-
Definium Therapeutics (DFTX) Reiterated at Overweight by Cantor Fitzgerald
-
Jefferies Starts Definium Therapeutics Inc (DFTX) at Buy
-
Definium Therapeutics Inc (DFTX) PT Raised to $36 at RBC Capital
-
Definium Therapeutics launches educational campaign on LSD research
-
Definium Therapeutics delays ticker change to DFTX until January 15


